Health Catalyst (NASDAQ:HCAT) Price Target Cut to $2.00 by Analysts at Citigroup

Health Catalyst (NASDAQ:HCAT) had its price target decreased by stock analysts at Citigroup from $2.50 to $2.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Citigroup’s target price points to a potential upside of 12.04% from the stock’s previous close.

A number of other research firms also recently commented on HCAT. Stephens dropped their price target on shares of Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Health Catalyst in a research note on Monday, May 11th. Canaccord Genuity Group boosted their target price on Health Catalyst from $2.00 to $3.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Weiss Ratings upgraded Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. Finally, Wells Fargo & Company increased their price target on Health Catalyst from $1.00 to $1.75 and gave the company an “equal weight” rating in a research note on Friday, June 26th. Four analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $2.95.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT traded up $0.07 on Tuesday, hitting $1.78. The company’s stock had a trading volume of 1,920,062 shares, compared to its average volume of 1,116,998. Health Catalyst has a 12 month low of $0.96 and a 12 month high of $3.80. The company has a market capitalization of $134.34 million, a price-to-earnings ratio of -0.49 and a beta of 1.55. The stock’s 50-day moving average is $1.99 and its two-hundred day moving average is $1.70. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.69 and a current ratio of 1.69.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. Health Catalyst had a negative return on equity of 1.57% and a negative net margin of 90.61%.The company had revenue of $70.49 million for the quarter, compared to analyst estimates of $69.09 million. On average, equities research analysts forecast that Health Catalyst will post -0.25 EPS for the current year.

Hedge Funds Weigh In On Health Catalyst

Several hedge funds have recently made changes to their positions in the business. HighMark Wealth Management LLC grew its position in Health Catalyst by 139.0% in the fourth quarter. HighMark Wealth Management LLC now owns 741,482 shares of the company’s stock worth $1,772,000 after buying an additional 431,200 shares during the last quarter. UBS Group AG lifted its position in shares of Health Catalyst by 10.0% during the 3rd quarter. UBS Group AG now owns 197,314 shares of the company’s stock valued at $562,000 after acquiring an additional 17,887 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Health Catalyst by 26.2% during the 2nd quarter. American Century Companies Inc. now owns 148,858 shares of the company’s stock valued at $561,000 after acquiring an additional 30,884 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Health Catalyst by 13.5% during the 2nd quarter. Rhumbline Advisers now owns 101,986 shares of the company’s stock worth $384,000 after acquiring an additional 12,127 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of Health Catalyst by 7.3% during the 4th quarter. Barclays PLC now owns 148,186 shares of the company’s stock worth $354,000 after acquiring an additional 10,100 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.